Article History
Accepted: 4 March 2022
First Online: 30 March 2022
Change Date: 6 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41571-022-00632-2
Competing interests
: M.J.P. has been a consultant for Aileron Therapeutics, AstraZeneca, Cygnal Therapeutics, Elstar Therapeutics, ImmuneOncia, KSQ Therapeutics, Merck, Siamab Therapeutics, Third Rock Ventures and Tidal. O.M. has been a consultant for Amgen, BMS, GSK, MSD, Novartis, Pierre Fabre and Roche, and has received research support from Amgen, BMS, MSD, Neracare and Pierre Fabre. D.M. is an inventor on patents related to CAR T cell therapy, filed by the University of Pennsylvania and the University of Geneva, and has been a consultant for Limula Therapeutics and MPC Therapeutics.